# US 2008/0307537 A1 · Compositions and Methods for the Identification, Assessment, Prevention, and Therapy of Neurological Diseases, Disorders and Conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0307537 A1
- Document ID: US20080307537A1
- Status: Published application
- Kind: A1
- Application number: 11/910,144
- Filed: 2006-03-21
- Published: 2008-12-11
- Earliest claimed: 2005-03-31
- Assignees: Dana-Farber Cancer Institute, Inc.
- Inventors: Robert M. Bachoo
- Web page: https://patentgrep.com/patent/US20080307537A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

A material comprising a plurality of closed cells is provided, the space within each cell being substantially evacuated. This may be achieved by sealing a dimpled film to a sealing film in a vacuum so that each dimple is closed while under vacuum to form an evacuated closed cell.

## Claims

### Claim 1

A method of assessing whether a subject is afflicted with a neurological disease, disorder or condition, the method comprising comparing:
a) the amount and/or activity of at least one marker in a subject sample, wherein the at least one marker is selected from the group consisting of the markers listed in Table 2, and
b) the normal amount and/or activity of at the least one marker in a control sample from a subject not afflicted with a neurological disease, disorder or condition,
wherein modulation of the amount and/or activity of the at least one marker in the subject sample compared to the normal amount and/or activity is an indication that the subject is afflicted with a neurological disease, disorder or condition.

### Claim 2 (depends on 1)

The method of claim 1, wherein the amount or activity of at least one marker is compared.

### Claim 3

(canceled)

### Claim 4 (depends on 2)

The method of claim 2, wherein the amount of at least one marker is determined by determining the level of expression or by determining the copy number of the marker.

### Claim 5

(canceled)

### Claim 6 (depends on 4)

The method of claim 4, wherein the level of expression of the at least one marker is assessed by detecting the presence in the sample of a protein corresponding to the marker.

### Claim 7 (depends on 6)

The method of claim 6, wherein the presence of the protein is detected using a reagent which specifically binds the protein selected from the group consisting of an antibody, an antibody derivative, and an antibody fragment.

### Claim 8

(canceled)

### Claim 9 (depends on 4)

The method of claim 4, wherein the level of expression of the at least one marker in the sample is assessed by detecting the presence of a transcribed polynucleotide or portion thereof, wherein the transcribed polynucleotide comprises the marker.

### Claim 10 (depends on 9)

The method of claim 9, wherein the transcribed polynucleotide is an mRNA or a cDNA.

### Claim 11

(canceled)

### Claim 12 (depends on 9)

The method of claim 9, wherein the step of detecting further comprises amplifying the transcribed polynucleotide.

### Claim 13 (depends on 4)

The method of claim 4, wherein the level of expression of the at least one marker in the sample is assessed by detecting the presence in the sample of a transcribed polynucleotide which anneals with the marker or anneals with a portion of a polynucleotide wherein the polynucleotide comprises the at least one marker, under stringent hybridization conditions.

### Claim 14 (depends on 1)

The method of claim 1, wherein the subject sample is selected from the group consisting of neuroglial tissue, whole blood, serum, plasma, buccal scrape, saliva, cerebrospinal fluid, spinal fluid, urine and stool.

### Claim 15 (depends on 1)

The method of claim 1, wherein the at least one marker is selected from the subset of markers in listed in Table 5 or Table 7.

### Claim at position 16

16-21. (canceled)

### Claim 22

A method of selecting a composition capable of modulating a symptom of neurological disease, disorder or condition, the method comprising:
a) providing a sample comprising astrocytes;
b) contacting said sample with a test compound; and
c) determining the ability of the test compound to modulate the amount and/or activity of at least one marker, wherein the marker is selected from the group consisting of the markers listed in Table 2; and
thereby identifying a composition capable of modulating a symptom of a neurological disease, disorder or condition.

### Claim 23 (depends on 22)

The method of claim 22, wherein the astrocytes are isolated from an animal model of a neurological disease, disorder or condition.

### Claim 24 (depends on 22)

The method of claim 22, wherein the astrocytes are isolated from a neural cell line.

### Claim 25 (depends on 22)

The method of claim 22, wherein the astrocytes are isolated from a subject suffering from a neurological disease, disorder or condition.

### Claim 26 (depends on 22)

The method of claim 22, further comprising administering the test compound to an animal model of a neurological disease, disorder or condition.

### Claim 27 (depends on 22)

The method of claim 22, wherein the at least one marker is selected from the subset of markers listed in Table 5 or Table 7.

### Claim 28

A method of treating a subject afflicted with a neurological disease, disorder or condition comprising administering to the subject a therapeutically effective amount of a compound which modulates the amount and/or activity of a gene or protein corresponding to at least one marker listed in Table 2, thereby treating a subject afflicted with a neurological disease, disorder or condition.

### Claim 29 (depends on 28)

The method of claim 28, wherein the at least one marker is selected from the subset of markers listed in Table 5 or Table 7.

### Claim at position 25

30-44. (canceled)

### Claim 45

A kit for assessing whether a subject is afflicted with a neurological disease, disorder or condition, the kit comprising reagents for assessing the amount and/or activity of at least one marker selected from the group consisting of the markers listed in Table 2.

### Claim 46 (depends on 45)

The kit of claim 45, wherein the at least one marker is selected from the subset of markers listed in Table 5 or Table 7.

### Claim at position 28

47-53. (canceled)

### Claim 54

A recombinant vector comprising an astrocyte-specific promoter operably linked to a Cre recombinase.

### Claim 55 (depends on 54)

The recombinant vector of claim 54, wherein said vector further comprises an inducible fusion protein.

### Claim at position 31

56-57. (canceled)

### Claim 58 (depends on 54)

A cell or cell line comprising the recombinant vector of claim 54.

### Claim 59 (depends on 54)

A non-human animal containing the recombinant vector of claim 54.

### Claim at position 34

60-72. (canceled)
